Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results

Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress

February 3, 2016 8:07 AM EST

Mizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings report. MYGN beat consensus revenues by $5mm and EPS by $0.04. However, Mizuho remains sidelined until more progress on reimbursement is seen.

Analyst Eric Criscuolo... More

Myriad Genetics (MYGN) Tops Q2 EPS by 4c

February 2, 2016 4:06 PM EST

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

... More